Sun Pharma gets relief from U.S. court

Drugmaker Sun Pharma on Thursday said the U.S. Court of Appeals for the Federal Circuit has vacated a preliminary injunction effective immediately that thus far restricted the company from launching severe alopecia areata drug Leqselvi (deuruxolitinib) in the U.S.

While the litigation, in a patent infringement case, with Incyte Corporation continues, the preliminary injunction granted by the U.S. District Court for the District of New Jersey’s is no longer in effect. Consequently, the company is no longer under a court order that delays or restricts it from launching Leqselvi. It will disclose Leqselvi launch plans in due course of time, Sun Pharma said.

On April 9, the U.S. Court of Appeals for the Federal Circuit held an oral argument on the company’s appeal of the U.S. District Court for the District of New Jersey’s decision that previously granted a preliminary injunction delaying its launch of Leqselvi (deuruxolitinib) in the U.S.

Shortly after the oral argument concluded, the U.S. Court of Appeals for the Federal Circuit ruled in favour of the company and vacated the preliminary injunction effective immediately.